We are live on ! Find out more
NAMS icon

NewAmsterdam Pharma

171 hedge funds and large institutions have $3.96B invested in NewAmsterdam Pharma in 2026 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 67 increasing their positions, 49 reducing their positions, and 37 closing their positions.

New
Increased
Maintained
Reduced
Closed

72% more capital inflows, than outflows

Capital inflows: $345M | Capital outflows: $200M

37% more repeat investments, than reductions

Existing positions increased: 67 | Existing positions reduced: 49

14% more funds holding in top 10

Funds holding in top 10: 7 → 8 (+1)

2.32% more ownership

Funds ownership: 105.22% → 107.55% (+2.3%)

9% less funds holding

Funds holding: 187 → 171 (-16)

32% less first-time investments, than exits

New positions opened: 25 | Existing positions closed: 37

38% less call options, than puts

Call options by funds: $11M | Put options by funds: $17.7M

Holders
171
Holders Change
-16
Holders Change %
-8.56%
% of All Funds
2.07%
Holding in Top 10
8
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+14.29%
% of All Funds
0.1%
New
25
Increased
67
Reduced
49
Closed
37
Calls
$11​M
Puts
$17.7​M
Net Calls
-⁠$6.65​M
Net Calls Change
-⁠$1.83​M

NAMS Hedge Fund Activity: Q1 2026 in Review

171 of the 8,244 institutional investors tracked by Wall St. Rank reported a position in NewAmsterdam Pharma (NAMS) for Q1 2026, worth a combined $3.96B — down 5.4% from $4.19B a quarter earlier.

Sellers outnumbered buyers: 37 funds closed out of NAMS and 25 opened new positions — a net loss of 12 holders — while 49 trimmed existing stakes and 67 added.

The largest buyer was Fidelity Investments, adding an estimated $76.6M. The largest seller was Pictet Asset Management, cutting an estimated $24.1M.

  • 171 institutional investors held NewAmsterdam Pharma (NAMS) as of Q1 2026, down from 187 in Q4 2025.
  • Funds reported $3.96B of NewAmsterdam Pharma stock for Q1 2026, down 5.4% quarter-over-quarter.
  • 25 funds opened new NewAmsterdam Pharma positions in Q1 2026 and 37 closed out, a net change of -12 holders.
  • The largest NewAmsterdam Pharma buyer in Q1 2026 was Fidelity Investments, an estimated $76.6M added.
  • The largest NewAmsterdam Pharma seller in Q1 2026 was Pictet Asset Management, an estimated $24.1M sold.

Based on aggregated 13F filings for Q1 2026.